Table 1.
Biochemical characterization of 1–10, controls 11, 12, auranofin (AF), praziquantel (PZQ), meclonazepam (MZM) and photoreactive probe (PRP)
ID | S. mansoni TGR IC50 (µM)a | S. mansoni TGR inhibition (%) at 66.7 µMb | Human TrxR1 IC50 (µM)a | Human TrxR1 IC50 (µM) or inhibition (%) at 66.7 µMb | Human GR (inhibition at 66.7 µM) | Decrease (%) in GSH/GSSG ratioc | |
---|---|---|---|---|---|---|---|
Slow TGR inhibitors | 1 | >66.7 | 42.1% | >66.7 | 37.0 ± 3.44 | n.i. | 75 |
2 | >66.7 | 28.7% | >66.7 | 50.0 ± 13.6 | n.i. | 39 | |
3 | >66.7 | 45.0% | >66.7 | 42.7 ± 3.95 | n.i. | 62 | |
4 | >66.7 | 68.6% | >66.7 | 19.0 ± 5.72 | n.i. | 60 | |
5 | >66.7 | 73.0% | >66.7 | 28.5% | n.i. | 56 | |
Fast TGR inhibitors | 6 | 2.5 ± 0.51 | — | >66.7 | 28.9% | n.i. | 32 |
7 | 14.6 ± 1.22 | — | 22.3 ± 2.03 | — | n.i. | 38 | |
8 | 10.3 ± 2.01 | — | 4.9 ± 1.72 | — | n.i. | 20 | |
9 | 57.5 ± 2.46 | — | 70.5 ± 11.4 | — | n.i. | 9 | |
10 | 18.6 ± 2.48 | — | 13.4 ± 2.0 | — | n.i. | n.d.d | |
Control | 11 | n.i.e | n.i.e | n. d.d | n.d.d | n.i. | 0.4 |
12 | n.i.e | n.i.e | >66.7 | 28.6% | n.i. | 1.7 | |
PRPf | 34.9 ± 6.11 | — | n.d.d | n.d.d | n.d.d | n.d.d | |
AF | 0.007 | — | 0.02 | — | n.d.d | 91 | |
PZQ | — | n.i.e | — | n.i.e | n.d.d | 1 | |
MZM | — | n.i.e | — | n.i.e | n.d.d | 1 |
Data are represented by n = 3 independent experiments as mean ± SD. Source data are provided as a Source Data file.
aIC50 after 15 min preincubation (enzyme + 100 µM NADPH + compound).
bIC50 (µM) or inhibition (%) at 66.7 µM (enzyme + 100 µM NADPH + compound) after 6 h preincubation. Inhibition (%) of TGR activity after 6 h incubation are given and not IC50s because equilibrium between enzyme and inhibitor was not obtained in this time frame (Fig. 3d).
cratio of GSH/GSSG in adult worms determined after 3 h exposure to compounds at 50 μM.
dn.d. not determined.
en.i. no inhibition at 67 μM in 6 h.
fPRP is a “slow” inhibitor.